|1.||Zeuzem, Stefan: 25 articles (06/2015 - 09/2007)|
|2.||Kobayashi, Hiroshi: 17 articles (01/2013 - 03/2002)|
|3.||Lawitz, Eric: 15 articles (01/2016 - 04/2012)|
|4.||Pol, Stanislas: 15 articles (10/2015 - 01/2006)|
|5.||Manfredi, Roberto: 14 articles (02/2014 - 01/2004)|
|6.||Sulkowski, Mark S: 13 articles (07/2014 - 01/2002)|
|7.||Suzuki, Mika: 13 articles (01/2005 - 03/2002)|
|8.||Marcellin, Patrick: 12 articles (05/2015 - 12/2010)|
|9.||Terao, Toshihiko: 12 articles (11/2004 - 03/2002)|
|10.||Kanayama, Naohiro: 12 articles (11/2004 - 03/2002)|
10/11/1999 - "Human immunodeficiency virus 1 (HIV-1) protease inhibitors have dramatically reduced the morbidity and mortality due to HIV-1 infection. "
10/27/2006 - "The introduction of human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs) markedly improved the clinical outcome and control of HIV-1 infection. "
12/21/2013 - "The addition of HCV protease inhibitors to the SOC has significantly improved the efficacy of treatments for HCV infection. "
01/01/2015 - "The addition of protease inhibitors (PIs) changed the hepatitis C virus (HCV) treatment standards and improved sustained viral response (SVR) rates in patients with genotype 1 HCV infection. "
10/01/2012 - "Protease inhibitors have improved sustained virological response (SVR) rates for subjects with genotype 1 hepatitis C virus infection (HCV). "
11/01/1999 - "These results indicate that intraperitoneal leakage of PLA2 plays an important role in bacterial translocation during acute pancreatitis and that administration of a protease inhibitor may be effective against the bacterial translocation."
01/01/2007 - "Additional research is needed to confirm the preventive efficacy of these antiproteases in patients at a high risk of developing post-ERCP pancreatitis."
10/01/2000 - "Therapeutic efficacy of continuous arterial infusion of an antibiotic and a protease inhibitor via the superior mesenteric artery for acute pancreatitis in an animal model."
04/01/2008 - "Protease inhibitors showed protective effects on animal models of acute pancreatitis when administered before induction of pancreatitis, and results when administered after induction are uncertain. "
01/01/2009 - "This study provides a clear rationale for further research to investigate the efficacy of enteral protease inhibitors in the treatment of acute pancreatitis."
|3.||HIV Infections (HIV Infection)
08/01/2007 - "Protease inhibitors were a major therapeutic breakthrough in the mid-1990s for the treatment of HIV infection, which resulted in improved life expectancy for patients who had failed previous therapies. "
05/12/1999 - "Combination antiretroviral therapy including protease inhibitors (combo+PI) is effective in suppressing systemic viral load in HIV infection, but its impact on HIV-associated cognitive impairment is unclear. "
06/01/2010 - "[Long-term efficacy of second-line treatment of HIV infection after class change following virological failure on protease inhibitor-based therapy]."
03/01/2003 - "Having changed the landscape in the treatment of HIV infection, the functional efficacy of current protease inhibitors (PIs) remains limited by their pharmacokinetic and pharmacodynamic profiles. "
02/01/1999 - "The advent of improved medical therapy with multidrug HIV medicines including protease inhibitors has prolonged life expectation of patients with HIV infection. "
|4.||Acquired Immunodeficiency Syndrome (AIDS)
07/01/2004 - "Although new treatments have significantly improved the physical health of those living with HIV/AIDS, no evidence was found that these treatments significantly improved psychological health for women, regardless of history of protease inhibitor use."
02/01/2002 - "Protease inhibitor combination therapies have significantly improved the health of many people with HIV/AIDS. "
09/01/1997 - "The safety and efficacy of two successive sessions of WBHT (4 days apart) was evaluated in 30 patients with AIDS (not on protease inhibitors), randomized to: 1) untreated controls, 2) low temperature WBHT for 1 hour at 40 degrees C and repeated 96 hours later, and 3) high temperature WBHT for 1 hour at 42 degrees C and repeated 96 hours later. "
10/01/2008 - "Therefore, the incomplete suppression of HIV in treatment-experienced AIDS patients will continue to drive the search for more effective therapeutic agents that exhibit efficacy against the mutants raised by the earlier generation of protease inhibitors. "
09/01/1997 - "Double protease inhibitor combinations may be effective in some AIDS patients who do not respond to or who are intolerant of routines with a single protease inhibitor, according to an in vitro study at Harvard. "
01/01/2015 - "The first generation protease inhibitors has been the mainstay of hepatitis C treatment for the last couple of years, showing marked improvement in sustained virological response, but also increased side effects. "
10/01/2014 - "With the introduction of the first-generation protease inhibitors the efficacy of hepatitis C treatment improved significantly. "
03/01/2013 - "An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver."
01/01/2013 - "A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients."
11/01/2015 - "Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake."
|5.||N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamide
|7.||Reverse Transcriptase Inhibitors
|8.||Protease Inhibitors (Protease Inhibitor)
|1.||Highly Active Antiretroviral Therapy (HAART)
|5.||Drug Therapy (Chemotherapy)